scholarly journals Economic evaluation of passive monitoring technology for seniors

2019 ◽  
Vol 32 (7) ◽  
pp. 1375-1382
Author(s):  
John E. Schneider ◽  
Jacie Cooper ◽  
Cara Scheibling ◽  
Anjani Parikh
Keyword(s):  
Health Care ◽  
Conceptual Model ◽  
Independent Living ◽  
Care Pathway ◽  
Cost Savings ◽  
Cost Benefit ◽  
Standard Of Care ◽  
Passive Monitoring ◽  
Monitoring Technology ◽  
The Cost

Abstract Background Advances such as passive monitoring technology (PMT), which provides holistic supervision of chronically ill and elderly patients, enable and support improved monitoring and observation, thus empowering the growing population of older adults to live more independently while lowering health care expenses. Aims This study develops a conceptual model to estimate the potential savings associated with PMT. Methods We first develop a conceptual model to identify the main cost variables associated with independent living, focusing on three pathways: (1) PMT, (2) independent living supported by the current standard of care, and (3) facility-based care. We examined the impact on three outcomes [i.e., health care costs, institutional costs, and health-related quality of life (HRQoL)] along each of the three care pathways (i.e., PMT, independent living supported by the standard of care, and facility-based care) and developed a cost-benefit model to calculate the net costs and benefits associated with each care pathway. Results The cost–benefit model showed savings between approximately $425 per-member per-month (PMPM) for those using PMT compared to those on the standard of care pathway. Sensitivity analysis demonstrated that a 5% increase in nursing home utilization generates cost savings of more than 30% PMPM. Discussion The total projected cost savings for individuals on the PMT arm are projected to be more than $425 PMPM, with annual savings of $5069 per-person per-year, and over $5.1 million for a target population of 1000 individuals. Conclusions The cost calculations in our cost–benefit simulation model clearly demonstrate the value of PMT and show the potential value to payers and integrated delivery systems in offering PMT to individuals who are likely to benefit the most from the services.

Home Visitation Investment

PEDIATRICS ◽  
1992 ◽  
Vol 89 (1) ◽  
pp. 169-169
Author(s):  
NORMAN J. SISSMAN
Keyword(s):  
Health Care ◽  
Home Visits ◽  
Cost Benefit ◽  
Home Visitation ◽  
Benefit Ratio ◽  
Health Care Resources ◽  
Detailed Consideration ◽  
Cost Benefit Ratio ◽  
Women And Children ◽  
The Cost

To the Editor.— Two recent reviews in Pediatrics1,2 provide much interesting information on the effect of home visits on the health of women and children. However, I was disappointed not to find in either article more than token reference to the cost of the programs reviewed. In this day of increasingly scarce health care resources, we no longer have the luxury of evaluating programs such as these without detailed consideration of their cost-benefit ratio.

scholarly journals Cost–effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain

2021 ◽  
Author(s):  
Kit N Simpson ◽  
Michael J Fossler ◽  
Linda Wase ◽  
Mark A Demitrack
Keyword(s):  
Cost Benefit Analysis ◽  
Cost Savings ◽  
Cost Benefit ◽  
Cost Effective ◽  
Adverse Outcomes ◽  
Protein Signaling ◽  
Opioid Receptor Agonist ◽  
Cost Effective Alternative ◽  
Μ Opioid Receptor ◽  
The Cost

Aim: Oliceridine, a new class of μ-opioid receptor agonist, is selective for G-protein signaling (analgesia) with limited recruitment of β-arrestin (associated with adverse outcomes) and may provide a cost-effective alternative versus conventional opioid morphine for postoperative pain. Patients & methods: Using a decision tree with a 24-h time horizon, we calculated costs for medication and management of three most common adverse events (AEs; oxygen saturation <90%, vomiting and somnolence) following postoperative oliceridine or morphine use. Results: Using oliceridine, the cost for managing AEs was US$528,424 versus $852,429 for morphine, with a net cost savings of $324,005. Conclusion: Oliceridine has a favorable overall impact on the total cost of postoperative care compared with the use of the conventional opioid morphine.

An Economic Analysis and Approach for Health Care Preparedness in a Substate Region

2015 ◽  
Vol 9 (4) ◽  
pp. 344-348 ◽  
Author(s):  
Benoit Stryckman ◽  
Thomas L. Grace ◽  
Peter Schwarz ◽  
David Marcozzi
Keyword(s):  
Health Care ◽  
Emergency Response ◽  
Return On Investment ◽  
Catchment Area ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Benefit Analysis ◽  
Response Team ◽  
The Cost ◽  
Positive Return

AbstractObjectiveTo demonstrate the application of economics to health care preparedness by estimating the financial return on investment in a substate regional emergency response team and to develop a financial model aimed at sustaining community-level disaster readiness.MethodsEconomic evaluation methods were applied to the experience of a regional Pennsylvania response capability. A cost-benefit analysis was performed by using information on funding of the response team and 17 real-world events the team responded to between 2008 and 2013. By use of the results of the cost-benefit analysis as well as information on the response team’s catchment area, a risk-based insurance-like membership model was built.ResultsThe cost-benefit analysis showed a positive return after 6 years of investment in the regional emergency response team. Financial modeling allowed for the calculation of premiums for 2 types of providers within the emergency response team’s catchment area: hospitals and long-term care facilities.ConclusionThe analysis indicated that preparedness activities have a positive return on their investment in this substate region. By applying economic principles, communities can estimate their return on investment to make better business decisions in an effort to increase the sustainability of emergency preparedness programs at the regional level. (Disaster Med Public Health Preparedness. 2015;9:344–348)

Cost-benefit analysis of AR-V7 testing in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) eligible for abiraterone (Abi) or enzalutamide (Enza).

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 283-283
Author(s):  
Mark Christopher Markowski ◽  
Kevin D. Frick ◽  
James R. Eshleman ◽  
Jun Luo ◽  
Emmanuel S. Antonarakis
Keyword(s):  
Cost Benefit Analysis ◽  
Cost Savings ◽  
Cost Benefit ◽  
Benefit Analysis ◽  
Castration Resistant Prostate Cancer ◽  
The Us ◽  
Effective Option ◽  
Current Price ◽  
Societal Challenge ◽  
The Cost

283 Background: The rising cost of oncology care in the US is an ongoing societal challenge, and identifying biomarkers that inform clinical decisions and reduce the use of ineffective therapies remains elusive. A splice variant of the androgen receptor, AR-V7, was found to confer resistance to Abi and Enza in men with mCRPC, but did not negatively affect responses to taxanes, suggesting that early use of chemotherapy may be a more effective option for AR-V7(+) pts. With the recent development of a CLIA-certified clinical assay for AR-V7 at Johns Hopkins, we hypothesized that AR-V7 testing in mCRPC pts may result in cost savings by avoiding futile treatment with Abi/Enza in men with AR-V7(+) disease. Methods: We calculated the cost savings of performing AR-V7 testing in mCRPC pts prior to starting Abi/Enza (and avoiding these drugs in AR-V7(+) men) versus treating all mCRPC pts with Abi/Enza (without use of the biomarker). We have set the cost of the AR-V7 assay at $1000. The cost of 3 months of Abi/Enza (the minimum time it would take to determine resistance, clinically) was approximated at $20,000. We estimated that 30,000 mCRPC pts per year are eligible for Abi/Enza in the US. Results: In our prior studies, about 30% of mCRPC pts previously treated with Abi/Enza had detectable AR-V7 in CTCs. Assuming an AR-V7 prevalence of 30%, about 9,000 AR-V7(+) mCRPC pts per year would receive ineffective treatment with Abi/Enza, at an estimated cost of $180 Million. The upfront cost of testing all mCRPC pts who are Abi/Enza-eligible for AR-V7 is $30 Million, resulting in a net cost savings of $150 Million. When performing a continuous cost-benefit analysis after assuming other prevalences of AR-V7 (ranging from 4% to 50%) and a range of costs for Abi/Enza ($2000 to $24,000 per 3 months), we determined that AR-V7 testing would result in a cost savings as long as the prevalence of AR-V7 is > 5% (if the cost of 3 months of Abi/Enza remains at $20,000). Conclusions: AR-V7 testing in mCRPC pts (at $1000/test) is cost-beneficial when considering the current price of Abi/Enza, and may reduce the ineffective use of Abi/Enza leading to a net cost savings to the healthcare system.

Cost/benefit of synbiotics in acute infectious gastroenteritis: spend to save

2012 ◽  
Vol 3 (3) ◽  
pp. 189-194 ◽  
Author(s):  
Y. Vandenplas ◽  
S. De Hert
Keyword(s):  
Health Care ◽  
Placebo Group ◽  
Concomitant Medication ◽  
Health Care Cost ◽  
Cost Benefit ◽  
Food Supplement ◽  
Food Supplementation ◽  
Ambulatory Treatment ◽  
Infectious Gastroenteritis ◽  
The Cost

The cost/benefit ratio of probiotics in the ambulatory treatment of acute infectious gastro-enteritis with or without a synbiotic food supplement (containing fructo-oligosaccharides and probiotic strains of Streptoccoccus thermophilus, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium lactis and Bifidobacterium infantis) has been studied. 111 children (median age 37 and 43 months for the synbiotic and placebo group, respectively) with acute infectious gastroenteritis were included in a randomised, prospective placebo-controlled trial performed in primary health care. All children were treated with an oral rehydration solution and with the synbiotic food supplement (n=57) or placebo (n=54). Physicians were allowed to prescribe additional medication according to what they considered as ‘necessary’. Cost of add-on medication and total healthcare cost were calculated. Median duration of diarrhoea was 1 day shorter (95% confidence interval -0.6 to -1.9 days) in the symbiotic than in the placebo group (P<0.005). Significantly more concomitant medication (antibiotics, antipyretics, antiemetics) was prescribed in the placebo group (39 prescriptions in 28 patients) compared to the synbiotic group (12 prescriptions in 7 patients) (P<0.001). The difference was most striking for antiemetics: 28 vs. 5 prescriptions. The cost of add-on medication in the placebo group was evaluated at € 4.04/patient (median 4.97 (interquartile (IQ) 25-75: 0-4.97)) vs. € 1.13 /patient in the synbiotic arm (P<0.001). If the cost of the synbiotic is considered, median cost raised to € 7.15/patient (IQ 25-75: 7.15-7.15) (P<0.001). The extra consultations needed to prescribe the concomitant medication resulted in a higher health care cost in the placebo group (€ 14.41 vs. € 10.74/patient, P<0.001). Synbiotic food supplementation resulted in a 24 h earlier normalisation of stool consistency. Although use of the synbiotic supplementation increased cost, add-on medication and extra consultations were reduced, resulting in a reduction of health care cost of 25%.

Biofutures: Race and the governance of health

2016 ◽  
Vol 35 (2) ◽  
pp. 222-240 ◽  
Author(s):  
Shiloh Krupar ◽  
Nadine Ehlers
Keyword(s):  
Health Care ◽  
Information System ◽  
Geographic Information System ◽  
Health Care System ◽  
Cost Benefit ◽  
Structural Racism ◽  
Gis Technologies ◽  
Spatial Profiling ◽  
The Cost ◽  
The U.S

This article addresses biomedical forms of racial targeting under neoliberal biopolitics. We explore two racial targeting technologies: The development of race-based pharmaceuticals, specifically BiDil; and medical hot spotting, a practice that uses Geographic Information System (GIS) technologies and spatial profiling to identify populations that are medically vulnerable in order to facilitate preemptive care. These technologies are ostensibly deployed under neoliberal biopolitics and the governance of health to affirm life. We argue, however, that these efforts further subject racial minorities—and specifically black subjects—to the cost–benefit logics of neoliberalism in the U.S. health care system and enduring anti-blackness. What is called for is an abolitionist biomedicine that recognizes and seeks to challenge the multifarious ways that race is ontologized as a corporeal and/or spatial truth while attending to the very real embodied effects of structural racism.

Comparing health care options using the cost-benefit utility ratio

JAMA ◽  
1986 ◽  
Vol 255 (6) ◽  
pp. 747b-747
Author(s):  
J. H. Steinbach
Keyword(s):  
Health Care ◽  
Cost Benefit ◽  
Health Care Options ◽  
The Cost

Cost Savings and Service Strategies in the British National Bibliographic Service

1989 ◽  
Vol 1 (2) ◽  
pp. 17-26
Author(s):  
Peter Lewis
Keyword(s):  
Action Plan ◽  
Cost Savings ◽  
Cost Benefit ◽  
International Standards ◽  
British Library ◽  
Library Community ◽  
Data Content ◽  
The Cost ◽  
Service Strategies

The British Library launched in 1986 a Catalogue Action Plan to deal with the long-term prospect of declining financial and manpower resources, the absence of growth in the market for its services, an unacceptably large backlog of uncatalogued materials, and a steadily increasing annual output of British publications to be catalogued. The initial phase of the Plan was designed to contain staff costs by reduction and simplification in data content in BNBMARC and other British Library records, predicating their future use primarily in an online (OPAC) environment. It has had significant success for the British Library's aims in the first full year of implementation, but it has raised questions of the cost-benefit in centralized cataloguing services for the library community, in respect both of the costs and sizing of OPAC systems in local libraries and of the necessity of sustaining indefinitely the high cost of adherence to international standards established before OPACs, the CD-ROMs and OSI had changed the technology.

scholarly journals Cardiovascular Magnetic Resonance Imaging—Incremental Value in a Series of 361 Patients Demonstrating Cost Savings and Clinical Benefits: An Outcome-Based Study

2017 ◽  
Vol 11 ◽  
pp. 117954681771002 ◽  
Author(s):  
Vinayak A Hegde ◽  
Robert WW Biederman ◽  
J Ronald Mikolich
Keyword(s):  
Magnetic Resonance Imaging ◽  
Health Care ◽  
Cardiovascular Magnetic Resonance ◽  
Magnetic Resonance ◽  
Cardiovascular Magnetic Resonance Imaging ◽  
Cost Savings ◽  
Cost Benefit ◽  
Clinical Impact ◽  
Resonance Imaging ◽  
Imaging Results

Background: This study was designed to assess the clinical impact and cost-benefit of cardiovascular magnetic resonance imaging (CMR). In the face of current health care cost concerns, cardiac imaging modalities have come under focused review. Data related to CMR clinical impact and cost-benefit are lacking. Methods and Results: Retrospective review of 361 consecutive patients (pts) who underwent CMR exams was conducted. Indications for CMR were tabulated for appropriateness criteria. Components of the CMR exam were identified along with evidence of clinical impact. The cost of each CMR exam was ascertained along with cost savings attributable to the CMR exam for calculation of an incremental cost-effectiveness ratio. A total of 354 of 361 pts (98%) had diagnostic quality studies. Of the 361 pts, 350 (97%) had at least 1 published Appropriateness Criterion for CMR. A significant clinical impact attributable to CMR exam results was observed in 256 of 361 pts (71%). The CMR exam resulted in a new diagnosis in 69 of 361 (27%) pts. Cardiovascular magnetic resonance imaging results avoided invasive procedures in 38 (11%) pts and prevented additional diagnostic testing in 26 (7%) pts. Comparison of health care savings using CMR as opposed to current standards of care showed a net cost savings of $833 037, ie, per patient cost savings of $2308. Conclusions: Cardiovascular magnetic resonance imaging provides diagnostic image quality in >98% of cases. Cardiovascular magnetic resonance imaging findings have documentable clinical impact on patient management in 71% of pts undergoing the exam, in a cost beneficial manner.

Sign in / Sign up

Export Citation Format

Share Document